Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis

Auris Nasus Larynx

Volumn 37, Issue 3, 2010, Pages 322-328

  Scheckenbach, Kathrin ^a   Cornely, Oliver ^c   Hoffmann, Thomas K ^a   Engers, Rainer ^a   Bier, Henning ^b   Chaker, Adam ^a   Greve, Jens ^a   Schipper, Jörg ^a   Wagenmann, Martin ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Amphotericin B; Fungal infection; Invasive rhinocerebral mucormycosis; Paranasal sinus; Posaconazole; Rhinosinusitis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; CEFUROXIME; GRANULOCYTE COLONY STIMULATING FACTOR; POSACONAZOLE;

AGED; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DEBRIDEMENT; DIABETES MELLITUS; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ETHMOIDECTOMY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; MUCORMYCOSIS; NOSE SURGERY; RHINOCEREBRAL MUCORMYCOSIS; RHINOSINUSITIS; SYMPTOM;

AGED; ANTIFUNGAL AGENTS; CENTRAL NERVOUS SYSTEM BACTERIAL INFECTIONS; FEMALE; HUMANS; MALE; MUCORMYCOSIS; RHINITIS; SEVERITY OF ILLNESS INDEX; TRIAZOLES;

EID: 77950535565     PISSN: 03858146     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anl.2009.09.001     Document Type: Article

References (60)

1. Paltauf A. Mycosis mucorina: Ein Beitrag zur Kenntnis der menschlichen Fadenpilzerkrankungen. Virchow Arch Pathol Anat 1885, 102:543-564.
2. Gregory J.E., Golden A., Haymaker W. Mucormycosis of the central nervous system. A report of 3 cases. Bull Johns Hopkins Hops 1943, 73:403-419.
3. Harris J.S. Mucormycosis; report of a case. Pediatrics 1955, December (16)(6):857-867.
4. Baker R.D. Mucormycosis; a new disease?. J Am Med Assoc 1957, 163(March (10)):805-808.
5. Chick E.W., Evans J., Baker R.D. Treatment of mucormycosis in rabbits with amphotherecin B. Antibiot Chemother 1958, 8:394-397.
6. Alleyne C.H., Vishteh A.G., Spetzler R.F., Detwiler P.W. Long-term survival of a patient with invasive cranial base rhinocerebral mucormycosis treated with combined endovascular, surgical, and medical therapies: case report. Neurosurgery 1999, 45(December (6)):1461-1463. discussion 1463-1464.
7. Sugar A.M. Mucormycosis. Clin Infect Dis 1992, 14(March (Suppl. 1)):S126-S129.
8. Goodman N.L., Rinaldi M.G. Agents of zygomycosis 1991, American Society of Microbiology, Washington DC. 5th ed.
9. Blitzer A., Lawson W. Fungal infections of the nose and paranasal sinuses. Part I. Otolaryngol Clin North Am 1993, 26(December (6)):1007-1035.
10. Gravesen S. Fungi as a cause of allergic disease. Allergy 1979, 34(June (3)):135-154.
11. Ferguson B.J. Mucormycosis of the nose and paranasal sinuses. Otolaryngol Clin North Am 2000, 33(April (2)):349-365.
12. Noble W.C., Clayton Y.M. Fungi in the air of hospital wards. J Gen Microbiol 1963, 32(September):397-402.
13. Baraia J., Munoz P., Bernaldo de Quiros J.C., Bouza E. Cutaneous mucormycosis in a heart transplant patient associated with a peripheral catheter. Eur J Clin Microbiol Infect Dis 1995, 14(September (9)):813-815.
14. Stern L.E., Kagan R.J. Rhinocerebral mucormycosis in patients with burns: case report and review of the literature. J Burn Care Rehabil 1999, 20(July-August (4)):303-306.
15. Cocanour C.S., Miller-Crotchett P., Reed R.L., Johnson P.C., Fischer R.P. Mucormycosis in trauma patients. J Trauma 1992, 32(January (1)):12-15.
16. Galetta S.L., Wulc A.E., Goldberg H.I., Nichols C.W., Glaser J.S. Rhinocerebral mucormycosis: management and survival after carotid occlusion. Ann Neurol 1990, 28(July (1)):103-107.
17. Hosseini S.M., Borghei P. Rhinocerebral mucormycosis: pathways of spread. Eur Arch Otorhinolaryngol 2005, (May).
18. Pagano L., Ricci P., Tonso A., Nosari A., Cudillo L., Montillo M., et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA infection program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto). Br J Haematol 1997, 99(November (2)):331-336.
19. Peterson K.L., Wang M., Canalis R.F., Abemayor E. Rhinocerebral mucormycosis: evolution of the disease and treatment options. Laryngoscope 1997, 107(Jul (7)):855-862.
20. Ferry A.P., Abedi S. Diagnosis and management of rhino-orbitocerebral mucormycosis (phycomycosis). A report of 16 personally observed cases. Ophthalmology 1983, 90(September (9)):1096-1104.
21. Yohai R.A., Bullock J.D., Aziz A.A., Markert R.J. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 1994, 39(July-August (1)):3-22.
22. Kline M.W. Mucormycosis in children: review of the literature and report of cases. Pediatr Infect Dis 1985, 4(November-December (6)):672-676.
23. Artis W.M., Fountain J.A., Delcher H.K., Jones H.E. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982, 31(December (12)):1109-1114.
24. Mathur S.C., Friedman H.D., Kende A.I., Davis R.L., Graziano S.L. Cryptic Mucor infection leading to massive cerebral infarction at initiation of antileukemic chemotherapy. Ann Hematol 1999, 78(May (5)):241-245.
25. Hopkins R.J., Rothman M., Fiore A., Goldblum S.E. Cerebral mucormycosis associated with intravenous drug use: three case reports and review. Clin Infect Dis 1994, 19(December (6)):1133-1137.
26. Rangel-Guerra R., Martinez H.R., Saenz C. Mucormycosis. Report of 11 cases. Arch Neurol 1985, 42(June (6)):578-581.
27. Boelaert J.R., Fenves A.Z., Coburn J.W. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991, 18(December (6)):660-667.
28. McNab A.A., McKelvie P. Iron overload is a risk factor for zygomycosis. Arch Ophthalmol 1997, 115(July (7)):919-921.
29. Scharf J.L., Soliman A.M. Chronic rhizopus invasive fungal rhinosinusitis in an immunocompetent host. Laryngoscope 2004, 114(September (9)):1533-1535.
30. Davel G., Featherston P., Fernandez A., Abrantes R., Canteros C., Rodero L., et al. Maxillary sinusitis caused by Actinomucor elegans. J Clin Microbiol 2001, 39(February (2)):740-742.
31. Ruoppi P., Dietz A., Nikanne E., Seppa J., Markkanen H., Nuutinen J. Paranasal sinus mucormycosis: a report of two cases. Acta Otolaryngol 2001, 121(December (8)):948-952.
32. Blitzer A., Lawson W., Meyers B.R., Biller H.F. Patient survival factors in paranasal sinus mucormycosis. Laryngoscope 1980, 90(April (4)):635-648.
33. DelGaudio J.M., Swain R.E., Kingdom T.T., Muller S., Hudgins P.A. Computed tomographic findings in patients with invasive fungal sinusitis. Arch Otolaryngol Head Neck Surg 2003, 129(February (2)):236-240.
34. Silverman C.S., Mancuso A.A. Periantral soft-tissue infiltration and its relevance to the early detection of invasive fungal sinusitis: CT and MR findings. AJNR Am J Neuroradiol 1998, 19(February (2)):321-325.
35. deShazo R.D., Chapin K., Swain R.E. Fungal sinusitis. N Engl J Med 1997, 337(July (4)):254-259.
36. Maiorano E., Favia G., Capodiferro S., Montagna M.T., Lo Muzio L. Combined mucormycosis and aspergillosis of the oro-sinonasal region in a patient affected by Castleman disease. Virchows Arch 2005, 446(January (1)):28-33.
37. Ribes J.A., Vanover-Sams C.L., Baker D.J. Zygomycetes in human disease. Clin Microbiol Rev 2000, 13(April (2)):236-301.
38. Tarrand J.J., Lichterfeld M., Warraich I., Luna M., Han X.Y., May G.S., et al. Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol 2003, 119(June (6)):854-858.
39. Ryan M., Yeo S., Maguire A., Webb D., O'Marcaigh A., McDermott M., et al. Rhinocerebral zygomycosis in childhood acute lymphoblastic leukaemia. Eur J Pediatr 2001, 160(April (4)):235-238.
40. Prabhu R.M., Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004, 10(March (Suppl. 1)):31-47.
41. Hall L., Wohlfiel S., Roberts G.D. Experience with the MicroSeq D2 large-subunit ribosomal DNA sequencing kit for identification of filamentous fungi encountered in the clinical laboratory. J Clin Microbiol 2004, 42(February (2)):622-626.
42. Turenne C.Y., Sanche S.E., Hoban D.J., Karlowsky J.A., Kabani A.M. Rapid identification of fungi by using the ITS2 genetic region and an automated fluorescent capillary electrophoresis system. J Clin Microbiol 1999, 37(June (6)):1846-1851.
43. Bhadada S., Bhansali A., Reddy K.S., Bhat R.V., Khandelwal N., Gupta A.K. Rhino-orbital-cerebral mucormycosis in type 1 diabetes mellitus. Indian J Pediatr 2005, 72(August (8)):671-674.
44. Smith J.L., Stevens D.A. Survival in cerebro-rhino-orbital zygomycosis and cavernous sinus thrombosis with combined therapy. South Med J 1986, 79(Apr (4)):501-504.
45. Fisher E.W., Toma A., Fisher P.H., Cheesman A.D. Rhinocerebral mucormycosis: use of liposomal amphotericin B. J Laryngol Otol 1991, 105(July (7)):575-577.
46. Penalver F.J., Romero R., Fores R., Cabrera R., Diez-Martin J.L., Regidor C., et al. Rhinocerebral mucormycosis following donor leukocyte infusion: successful treatment with liposomal amphotericin B and surgical debridement. Bone Marrow Transplant 1998, 22(October (8)):817-818.
47. Raj P., Vella E.J., Bickerton R.C. Successful treatment of rhinocerebral mucormycosis by a combination of aggressive surgical debridement and the use of systemic liposomal amphotericin B and local therapy with nebulized amphotericin-a case report. J Laryngol Otol 1998, 112(April (4)):367-370.
48. Strasser M.D., Kennedy R.J., Adam R.D. Rhinocerebral mucormycosis. Therapy with amphotericin B lipid complex. Arch Intern Med 1996, 156(February (3)):337-339.
49. Mondy K.E., Haughey B., Custer P.L., Wippold F.J., Ritchie D.J., Mundy L.M. Rhinocerebral mucormycosis in the era of lipid-based amphotericin B: case report and literature review. Pharmacotherapy 2002, 22(April (4)):519-526.
50. Luckhaupt H., Rose K.G. Mycoses of the ENT area. Hno 1995, 43(January (1)):39-48.
51. Christenson J.C., Shalit I., Welch D.F., Guruswamy A., Marks M.I. Synergistic action of amphotericin B and rifampin against Rhizopus species. Antimicrob Agents Chemother 1987, 31(November (11)):1775-1778.
52. Morrison V.A., Mc Glave P.B. Mucormycosis in the BMT population 1993. Bone Marrow Transplant 1993, 11:383-388.
53. Kajs-Wyllie M. Hyperbaric oxygen therapy for rhinocerebral fungal infection. J Neurosci Nurs 1995, 27(June (3)):174-181.
54. Sheehan D.J., Hitchcock C.A., Sibley C.M. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999, 12(January (1)):40-79.
55. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract 2004, 58(June (6)):612-624.
56. Kim H., Kumari P., Laughlin M., Hilbert M.J., Indelicato S.R., Lim J., et al. Use of high-performance liquid chromatographic and microbiological analyses for evaluating the presence or absence of active metabolites of the antifungal posaconazole in human plasma. J Chromatogr A 2003, 987(February (1-2)):243-248.
57. Ghosal A., Yuan Y., Hapangama N., Su A.D., Alvarez N., Chowdhury S.K., et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3-hydroxydesloratadine. Biopharm Drug Dispos 2004, 25(September (6)):243-252.
58. Wexler D., Courtney R., Richards W., Banfield C., Lim J., Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004, 21(April (5)):645-653.
59. Tobon A.M., Arango M., Fernandez D., Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis 2003, 36(June (11)):1488-1491.
60. Greenberg R.N., Scott L.J., Vaughn H.H., Ribes J.A. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004, 17(December (6)):517-525.